What is the actual difference between semaglutide and tirzepatide?

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist that engages both GIP and GLP-1 receptors. That receptor coverage is the core difference the literature examines.

Which has the longer reported half-life?

Published pharmacokinetic work reports roughly a week for semaglutide and around five days for tirzepatide.

Are both available in Australia for research?

Yes. Both are stocked in Australia, HPLC verified at ≥99% purity with a lot-matched Certificate of Analysis, and dispatched cold-chain same-day before 12pm AEST.

What about retatrutide?

Retatrutide is a triple agonist (GIP, GLP-1 and glucagon receptors) and is the newest of the three. Our retatrutide research guide covers how it differs.

Semaglutide vs Tirzepatide Australia

At a glance

	Semaglutide	Tirzepatide
Receptor targets	GLP-1	GIP + GLP-1 (dual agonist)
Class	Incretin mimetic peptide	Dual incretin mimetic peptide
Reported half-life in literature	≈ 1 week	≈ 5 days
Form supplied	Lyophilised powder, sealed vial	Lyophilised powder, sealed vial
Purity standard	HPLC ≥99%, lot-matched CoA	HPLC ≥99%, lot-matched CoA
Storage	-20°C lyophilised, 2-8°C reconstituted	-20°C lyophilised, 2-8°C reconstituted

Single agonist vs dual agonist

Semaglutide binds the GLP-1 receptor. It is the reference compound in most published incretin research and, because of that, the easiest to design a study around — there is a very large body of comparable data.

Tirzepatide engages both the GIP and GLP-1 receptors. The research interest is in whether the combined signalling produces effects that single-receptor agonism does not, which is why it appears in newer comparative literature.

Retatrutide extends the same idea to three receptors — if that is the direction of your work, our Retatrutide guide covers it.

Handling and reconstitution notes

Both arrive lyophilised in sealed vials with a lot number on the label. Reconstitution uses bacteriostatic water; the concentration you end up with is simply the vial's milligram content divided by the millilitres of water added.

After reconstitution, both are refrigerated at 2-8°C, kept out of light, and not repeatedly frozen and thawed. Record the lot number alongside your data so results stay traceable to a specific CoA.

Compliance in Australia

Both compounds are supplied strictly for in-vitro laboratory research. They are not therapeutic goods, hold no TGA approval for human use, and nothing on this page is a dosing protocol or a claim of benefit.

Questions people ask

What is the actual difference between semaglutide and tirzepatide?: Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist that engages both GIP and GLP-1 receptors. That receptor coverage is the core difference the literature examines.
Which has the longer reported half-life?: Published pharmacokinetic work reports roughly a week for semaglutide and around five days for tirzepatide.
Are both available in Australia for research?: Yes. Both are stocked in Australia, HPLC verified at ≥99% purity with a lot-matched Certificate of Analysis, and dispatched cold-chain same-day before 12pm AEST.
What about retatrutide?: Retatrutide is a triple agonist (GIP, GLP-1 and glucagon receptors) and is the newest of the three. Our retatrutide research guide covers how it differs.